Biogen’s $11 Billion Boom Erases 2019 Alzheimer’s Drug Struggle

(Bloomberg) -- Biogen Inc.’s rally of more than 30% Wednesday after it won a key patent dispute has some investors celebrating as they put last year’s concern surrounding a failed Alzheimer’s drug ...